CLINICAL_TRIALS
research
· 2014-10-22
Clinical Trial Update: Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer [Phase 2]
Summary
A Phase 2 clinical trial investigating chemotherapy plus icotinib for EGFR mutation-positive non-small-cell lung cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Nanfang Hospital, Southern Medical University | Conditions: NSCLC | Phase 2 | Status: UNKNOWN